While markers such as IL-6, TNF-alpha, and CRP have well-established relationships with depression in cancer patients (22), the present study focuses on IL-4, BDNF, and neopterin due to their unique and potentially significant roles in the inflammatory and neurotrophic pathways. Here, IL4 is linked to depressive symptom measurement.